AURA

Aura Biosciences, Inc. (AURA) | Rumor.io

Aura Biosciences

AURA

Attention (50-day avg)0%

Attention rank (50-day avg)#4,454

Bullish sentiment (50-day avg)100%

Price to earnings ratio-3.5

Market capitalization637.8M

Earnings per share-1.78

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-106.2M

Social

What share of all stock conversation is about AURA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 9

$AURA surged from a $9M to $60M market cap after a Binance meme post sparked listing speculation.
Binance has hinted at a potential $AURA listing, with some users speculating that the company is "coded for billions".
A $AURA whale has made significant purchases of the asset, buying $10.79K, $5K, $3.35K, and $6.99K of $AURA at various market caps.

Generated by AI

Sentiment

Of the messages about AURA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	97.22% +5.15
Bearish	—	—	0%	2.78% -5.15

Topics

Of the messages about AURA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	16.5%
Analysts	—	—	—	5.67%
Announcements	—	—	—	28.57%
Controversies	—	—	—	0.74%
Earnings	—	—	—	1.97%
Macro	—	—	—	46.55%

Nov 10

Aura Biosciences, Inc. (AURA) has reported its third-quarter 2022 financial results, showing meaningful clinical advances in its ocular and urologic oncology programs.
The company has announced the initiation of a global Phase 3 trial for its lead candidate, belzupacap sarotalocan, in early-stage choroidal melanoma, with a suprachoroidal route of administration.
Aura Biosciences has filed a Form 8-K with the SEC, disclosing its financial results for the third quarter of 2022 and providing clinical development and operational highlights.

Generated by AI

Community

Of the messages about AURA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	45.69%
Newcomers	—	—	100%	54.31%

Regulars· Nov 10

Aura Biosciences has announced a global Phase 3 trial design for Belzupacap Sarotalocan in early-stage choroidal melanoma, based on positive Phase 2 interim data.
The company has reported its third-quarter 2022 financial results, showing a focus on clinical development and operational highlights.
Aura Biosciences has filed its form 8-K with the SEC, detailing its third-quarter financial results and providing clinical development and operational highlights.

Newcomers· Jun 16

The newcomer community is excited about Aura Biosciences, Inc.'s (AURA) potential for growth, with some predicting easy 50 to 200x gains if they have enough patience.
Some new investors are comparing AURA to other clean tech plays, highlighting the company's unique features and potential for success in this space.
The AURA community is also discussing the stock's performance, with some noting that it may be due for a correction or that it has reached overbought conditions, while others are confident in its ability to continue growing.

Generated by AI

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference: Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.Fireside Chat at 2:35 p.m. ET The live webcast of the fireside chat will

27d agoYahoo Finance Singapore

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura’s new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura’s new Chief Operating Officer, and Julie Person, Aura’s new C

28d agoYahoo Finance

Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP)

Tipranks Press Release.

1mo agoThe Globe and Mail

Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval

1mo agoSeeking Alpha

H.C. Wainwright cuts Aura Biosciences stock price target on strategic shift

1mo agoInvesting.com

Also Discussed

Investors talking about AURA also mention

#	Name	Attention
1	Ameren CorporationAEE	0%new
2	3 E Network Technology Group Ltd Class A Ordinary SharesMASK	0%new
3	Traeger Inc.COOK	0%0
4	Ball Corp.BALL	0%0
5	SPX6900SPX	0.01%-0.01
6	Calamos Convertible Opportunities and Income FundCHI	0%0
7	ROT - Rotor Acquisition Corp.	——
8	The RealReal, Inc.REAL	0%0
9	Useless CoinUSELESS	0%-0.01
10	PopcatPOPCAT	0.01%+0

Aura Biosciences, Inc.

Healthcare
Biotechnology

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, with a particular emphasis on ocular cancers. Its lead program centers on belzupacap sarotalocan, a virus-like drug conjugate designed to selectively target cancer cells while preserving healthy tissue and organ function. The company’s platform is built around virus-like particles that deliver therapeutic payloads directly to tumors and support an immune response against cancer. Aura Biosciences is advancing its oncology pipeline across ocular oncology and other related indications, including bladder cancer, using a targeted approach intended for specialist treatment settings. Headquartered in Boston, Massachusetts, Aura Biosciences plays a focused role in the biotechnology market as a developer of novel cancer therapies for hard-to-treat solid tumors.

Website

Location

80 Guest Street

Boston, MA, 02135

United States

Social

What share of all stock conversation is about AURA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 9

$AURA surged from a $9M to $60M market cap after a Binance meme post sparked listing speculation.
Binance has hinted at a potential $AURA listing, with some users speculating that the company is "coded for billions".
A $AURA whale has made significant purchases of the asset, buying $10.79K, $5K, $3.35K, and $6.99K of $AURA at various market caps.

Generated by AI

Sentiment

Of the messages about AURA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	97.22% +5.15
Bearish	—	—	0%	2.78% -5.15

Topics

Of the messages about AURA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	16.5%
Analysts	—	—	—	5.67%
Announcements	—	—	—	28.57%
Controversies	—	—	—	0.74%
Earnings	—	—	—	1.97%
Macro	—	—	—	46.55%

Nov 10

Aura Biosciences, Inc. (AURA) has reported its third-quarter 2022 financial results, showing meaningful clinical advances in its ocular and urologic oncology programs.
The company has announced the initiation of a global Phase 3 trial for its lead candidate, belzupacap sarotalocan, in early-stage choroidal melanoma, with a suprachoroidal route of administration.
Aura Biosciences has filed a Form 8-K with the SEC, disclosing its financial results for the third quarter of 2022 and providing clinical development and operational highlights.

Generated by AI

Community

Of the messages about AURA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	45.69%
Newcomers	—	—	100%	54.31%

Regulars· Nov 10

Aura Biosciences has announced a global Phase 3 trial design for Belzupacap Sarotalocan in early-stage choroidal melanoma, based on positive Phase 2 interim data.
The company has reported its third-quarter 2022 financial results, showing a focus on clinical development and operational highlights.
Aura Biosciences has filed its form 8-K with the SEC, detailing its third-quarter financial results and providing clinical development and operational highlights.

Newcomers· Jun 16

The newcomer community is excited about Aura Biosciences, Inc.'s (AURA) potential for growth, with some predicting easy 50 to 200x gains if they have enough patience.
Some new investors are comparing AURA to other clean tech plays, highlighting the company's unique features and potential for success in this space.
The AURA community is also discussing the stock's performance, with some noting that it may be due for a correction or that it has reached overbought conditions, while others are confident in its ability to continue growing.

Generated by AI

Aura Biosciences

Social

May 9

Sentiment

Topics

Nov 10

Community

Regulars· Nov 10

Newcomers· Jun 16

News

Aura Biosciences at Morgan Stanley conference: bel-sar takes center stage

Aura Biosciences to Participate in Upcoming Investor Conference

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP)

Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval

H.C. Wainwright cuts Aura Biosciences stock price target on strategic shift

Also Discussed

Aura Biosciences, Inc.

Company Information

Location

News

Aura Biosciences at Morgan Stanley conference: bel-sar takes center stage

Aura Biosciences to Participate in Upcoming Investor Conference

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP)

Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval

H.C. Wainwright cuts Aura Biosciences stock price target on strategic shift

Also Discussed

Social

May 9

Sentiment

Topics

Nov 10

Community

Regulars· Nov 10

Newcomers· Jun 16